Navigation Links
Lexicon Announces Commencement of Rights Offering to Stockholders
Date:11/22/2011

to initiate a pro rata rights offering to its stockholders.  Invus, L.P. and Invus C.V. will be required to exercise their basic subscription privileges in full and purchase at least 68,868,892 shares of common stock in the rights offering, subject to certain customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  In light of the potential for the ownership percentage of Invus, L.P., Invus C.V. and their affiliates to increase to greater than 50% of Lexicon's outstanding common stock as a result of the rights offering, the parties have made the required filings for that purpose with the Premerger Notification Office of the Federal Trade Commission and the Antitrust Division of the Department of Justice.

Any questions from stockholders or requests for additional copies of the prospectus supplement and accompanying prospectus or other rights offering materials may be directed to BNY Mellon Shareowner Services, the information agent for the rights offering, at (800) 777-3674 from within the United States, Canada or Puerto Rico, or at (201) 680-6579 from outside the United States.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale is not permitted.  The offering of securities in the rights offering will be made only by means of the prospectus supplement and accompanying prospectus, copies of which may be obtained from BNY Mellon Shareowner Services as indicated above.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rhe
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
2. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
3. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
4. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
5. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
6. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
7. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
8. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
9. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
11. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Every year ... research to fight heart disease.  Nevertheless, year after year ... ElectroCardioGrams (EKG) as the first test to determine the ... have chest pain or not, even though that technology ... despite the fact that doctors know, (while most patients ...
(Date:2/26/2015)... Mass. , Feb. 26, 2015  Spring ... novel therapeutics for the treatment of Hepatitis B ... the closing of a $22 million financing. Funds ... SB 9200, a novel, broad spectrum antiviral agent ... nucleic acid hybrid (SMNH) chemistry platform, into Phase ...
(Date:2/26/2015)... 26, 2015  Lyric Pharmaceuticals Inc. today announced the ... $20.4 million. The financing, co-led by RiverVest Venture Partners, ... Aperture Venture Partners. Lyric is a ... Wurtman , M.D., M.B.A., President & Chief Executive Officer ... Officer.  In 2014, Lyric closed a seed financing round ...
Breaking Medicine Technology:National Heart Health Month In February 2Spring Bank Pharmaceuticals Completes $22 Million Financing 2
... NEW YORK, Sept. 13, 2011 IMMUNE ... based Therapeutics for the treatment of inflammatory diseases and ... M.D., Ph.D., to the position of Chief Medical Officer.  ... pivotal  role in the development of Bertilimumab, IMMUNE,s phase ...
... DIEGO, Sept. 13, 2011 Sequenom, Inc. (NASDAQ: ... solutions, today announced the Company,s participation at the UBS Global ... in New York City September 19-21, 2011. ... Development, will present on Monday, September 19, 2011 beginning at ...
Cached Medicine Technology:IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 2IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer 3Sequenom Announces Participation at UBS Global Life Sciences Conference 2
(Date:2/27/2015)... VA (PRWEB) February 27, 2015 The ... accepting applications for its next class of Fellows — ... field of radiology business management. , Since 2009, ... significant contributions made by RBMA members to the Association ... a prestigious recognition because each Fellow candidate must meet ...
(Date:2/27/2015)... The report “Polycystic Ovarian Syndrome ... on the therapeutic development for polycystic ovarian syndrome. ... a woman's hormones are out of balance. Polycystic ... girls and young women. The cause of polycystic ... pipelines by identifying new targets and MOAs to ...
(Date:2/27/2015)... February 27, 2015 Prescription Drug ... U.S. Drug Enforcement Agency (DEA). Today, ... continue to utilize the “Take-Back” guidelines for the ... FDA. , Eufaula Prescription Drug Disposal Event , ... Drive in Eufaula, Oklahoma as the “Take-Back” site ...
(Date:2/27/2015)... 27, 2015 ResearchMoz has announced ... the analysis of the cell culture protein surface ... discusses the current scenario and development prospects of ... for the period of 2015 to 2019. , ... , The research report, titled Global Cell ...
(Date:2/27/2015)... VT (PRWEB) February 27, 2015 The ... mitigation plan for alleged violations that date back to ... department was completed as soon as it was approved ... Hermitage didn't agree with the allegations we agreed to ... Hermitage Inn Real Estate Holding Company. , Barnes further ...
Breaking Medicine News(10 mins):Health News:RBMA Issues Call for Fellowship Applicants 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 2Health News:Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth 3Health News:Southern Vermont's Hermitage Club Announces Statement Regarding Vermont Attorney General Lawsuit for Permit Violations 2
... (NYSE: HUN ) will hold a conference call to discuss its ... 11:00 a.m. ET. Fourth quarter and full year 2007 results will be,released ... Call-in number for U.S. participants: ... Call-in number for international participants: (617) 213 - 4868 ...
... Spending Cuts, ALEXANDRIA, Va., Feb. 8 President ... to the future of,health and health care for all ... the nation,s single largest payer of children,s health care ... from,discretionary health programs that children depend on, ranging from ...
... Despite Difficulties, States Rise Against the Status Quo ... - A new report from the,Robert Wood Johnson ... 2008: Rising to the Challenge, outlines 2007 efforts ... to address health care,reform at the state level. ...
... NHS Choices ( http://www.nhs.uk ), the,online ,front ... news service to,help people make sense of the ... Behind the headlines, on NHS Choices,( http://www.nhs.uk/News/Pages/NewsIndex.aspx ), ... the news. The service explains the,facts behind newspaper ...
... Feb. 8 The Integrated,Healthcare Association (IHA) welcomes ... third annual National Pay for Performance Summit at ... summit is the,leading forum on pay for performance ... Leapfrog Group has made outstanding contributions toward the,improvement ...
... finds spouses die sooner in unions where anger is suppressed ... secret to a long marriage is communication, and new research ... , A lengthy study of Midwestern couples finds that those ... the perennially resentful. The couples with the most unexpressed anger ...
Cached Medicine News:Health News:Huntsman to Discuss Fourth Quarter and Full Year 2007 Results on Friday, February 22, 2008 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 2Health News:Bush Budget Cuts Federal Health Programs Vital to the Health of All Children 3Health News:Report Lists Key Policy Questions Facing State, National Health Reform 2Health News:Report Lists Key Policy Questions Facing State, National Health Reform 3Health News:Report Lists Key Policy Questions Facing State, National Health Reform 4Health News:Integrated Healthcare Association Welcomes Leah Binder, New CEO of Leapfrog Group to National Pay for Performance Summit 2Health News:Mutual Resentment in Marriage Can Be Deadly 2Health News:Mutual Resentment in Marriage Can Be Deadly 3
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
Medicine Products: